Table 3.

Multivariable regression analysis for outcome according to the MN1 expression status in all older patients with de novo CN-AML, and in those 70 years of age or older

End point	Variables in final models	OR/HR	95% CI	P
All patients
CR*	MN1, low vs high	3.16	1.29, 7.70	.01
	BAALC, low vs high	4.39	1.85, 10.44	< .001
	WBC, each 2-fold increase	0.76	0.62, 0.93	.01
EFS†	MN1, low vs high	0.54	0.34, 0.86	.03¶
	BAALC, low vs high	0.43	0.27, 0.68	.002¶
	WBC, each 2-fold increase	1.22	1.09, 1.35	< .001¶
	Platelets, each 50-unit increase	1.15	1.05, 1.25	.002
Patients 70 y or older
CR‡	MN1, low vs high	3.97	1.22, 12.90	.02
OS§	Interaction of MN1 and NPM1			.29
	Mutated NPM1:	0.41	0.17, 0.97	.04
	MN1, low vs high
	Wild-type NPM1:			.58
	MN1, low vs high
FS‖	Interaction of MN1 and NPM1			.14
	Mutated NPM1:	0.37	0.15, 0.88	.02
	MN1, low vs high
	Wild-type NPM1:			.87
	MN1, low vs high

OR > 1 (< 1) indicates higher (lower) CR rate for the higher values of the continuous variables and the first category listed for the categorical variables. HR > 1 (< 1) indicates higher (lower) risk for an event for the higher values of the continuous variables and the first category listed for the categorical variables.

^*Variables considered in the model based on univariable analyses were MN1 expression (high vs low; median cut), BAALC expression (high vs low; median cut), FLT3-ITD (positive vs negative), IDH2 (mutated vs wild-type), NPM1 (mutated vs wild-type), WBC (continuous, log base 2), and platelets (continuous, 50-unit increase).

^†Variables considered in the model based on univariable analyses were MN1 expression (high vs low; median cut), BAALC expression (high vs low; median cut), ERG expression (high vs low; median cut), FLT3-ITD (positive vs negative), IDH2 (mutated vs wild-type), NPM1 (mutated vs wild-type), WT1 (mutated vs wild-type), WBC (continuous, log base 2), and platelets (continuous, 50-unit increase).

^‡Variables considered in the model based on univariable analyses were MN1 expression (high vs low; median cut), BAALC, expression (high vs low; median cut), platelets (continuous, 50-unit increase), and NPM1 (mutated vs wild-type).

^§Variables considered in the model based on univariable analyses were MN1 expression (high vs low; median cut), BAALC, expression (high vs low; median cut), IDH1 (mutated vs wild-type), NPM1 (mutated vs wild-type), and platelets.

^‖Variables considered in the model based on univariable analyses were MN1 expression (high vs low; median cut), BAALC, expression (high vs low; median cut), IDH2 (mutated vs wild-type), NPM1 (mutated vs wild-type), and platelets.

^¶Does not meet the proportional hazards assumption. For EFS, the HR for BAALC, high vs low (median cut), MN1, high vs low (median cut), and WBC are reported at 3 months.